文献速递毛发、甲与色素性疾病

继续使用利特昔替尼至48周可维持斑秃患者毛发再生:ALLEGRO 2b/3期事后分析

Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial.
PubMed 文献 · J Am Acad Dermatol · 2024-10-17

该事后分析评估利特昔替尼持续治疗至48周的疗效与安全性。24周达到SALT≤20和≤10应答的患者中,分别≥85%和≥68%维持应答至48周;24周未达标者中22%-34%和20%-26%分别达到SALT≤20和≤10。安全性各亚组相似。

要点

  • 24周SALT≤20应答者中≥85%维持至48周
  • 24周SALT≤10应答者中≥68%维持至48周
  • 24周未达标者继续治疗至48周,最多约三分之一可达标

核心结论

  • 24周有应答的斑秃患者继续利特昔替尼治疗至48周可维持毛发再生。
  • 24周未达目标疗效者继续治疗至48周,最多约三分之一可达到应答。

研究设计与样本

  • ALLEGRO 2b/3期试验的事后分析,患者年龄≥12岁,每日接受利特昔替尼(±4周负荷剂量):200/50 mg、200/30 mg、50 mg或30 mg。
  • 基于24周SALT评分≤20和≤10评估临床应答,并评估应答维持至48周;24周无应答者评估至48周的应答。

主要发现

  • 24周SALT≤20应答的利特昔替尼治疗患者中,≥85%维持应答至48周。
  • 24周SALT≤10应答的利特昔替尼治疗患者中,≥68%维持应答至48周。
  • 24周SALT>20的患者中,22%至34%在48周达到SALT≤20。
  • 24周SALT>10的患者中,20%至26%在48周达到SALT≤10。
  • 各亚组安全性相似。

关键数值与推荐

  • 持续应答定义为24周SALT≤20或≤10应答维持至48周。
  • 24周未达标者评估48周达到SALT≤20或≤10的比例。

临床怎么用

  • 对24周有应答的斑秃患者,继续利特昔替尼治疗可维持疗效至48周。
  • 对24周未达标的患者,继续治疗至48周仍可能获得应答,最多约三分之一可达标。

局限性

  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few treatments for alopecia areata have demonstrated sustained efficacy. OBJECTIVE: Evaluate the efficacy and safety of continued ritlecitinib treatment to week 48 in patients with alopecia areata with or without target efficacy responses at week 24. METHODS: Patients aged ≥12 years received daily ritlecitinib (±4-week loading dose): 200/50 mg, 200/30 mg, 50 mg, or 30 mg. Patients with clinical response at week 24, based on a Severity of Alopecia Tool (SALT) score ≤20 and ≤10, were evaluated for sustained response through week 48. Nonresponders at week 24 were assessed for response through week 48. RESULTS: Among ritlecitinib-treated patients with SALT score ≤20 and ≤10 responses at week 24, ≥85% and ≥68%, respectively, sustained these responses through week 48. Of those with a SALT score >20 at week 24, 22% to 34% achieved a SALT score ≤20 at week 48. Of those with a SALT score >10 at week 24, 20% to 26% achieved a SALT score ≤10 at week 48. Safety was similar across subgroups. LIMITATIONS: Small sample size. CONCLUSION: Hair regrowth was sustained through week 48 in patients with response at week 24. Up to one-third of patients who did not meet target efficacy at week 24 achieved response with continued ritlecitinib treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Piliang M, Lynde C, King B, et al. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. J Am Acad Dermatol. 2024. PMID: 39423930. doi:10.1016/j.jaad.2024.09.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。